Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma - a case control study from western Nepal

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5773-5775

  Mittal, Ankush ^a   Gupta, Satrudhan Pd ^a   Sathian, Brijesh ^b   Sreedharan, Jayadevan ^c   Poudel, Bibek ^d   Yadav, Shambhu Kumar ^d   Pandeya, Dipendra Raj ^a  

^a Biochemistry   (Nepal)

^b Community Medicine ^*  (Nepal)

^c GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^d MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

Author keywords

AFP; Carboxyprothrombin; Des; Diagnosis; Gamma; HCC; Nepal

Indexed keywords

EID: 84874045815     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5773     Document Type: Article

References (14)

1. Bertino G, Ardiri AM, Calvagno GS, et al (2010). Prognostic and diagnostic value of des-?-carboxy prothrombin in liver cancer. Drug News Perspect, 23, 498-508.
2. Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
3. El-Attar HA, Kandil MH, El-Kerm YM, et al (2010). Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev, 11, 897-903.
4. Fujikawa T, Shiraha H, Yamamoto K (2009). Significance of desgamma- carboxyprothrombin production in hepatocellular carcinoma. Acta Med Okayama, 63, 299-304.
5. Fujiyama S, Izuno K, Gohshi K, et al (1991). Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci, 36, 1787-92.
6. Mittal A, Sathian B, Chandrashekharan N, et al (2011). Diagnostic significance of alpha fetoprotein in carcinomas of liver and biliary tract - a comparative study from the western region of Nepal. Asian Pac J Cancer Prev, 12, 3475-8.
7. Okuda H, Nakanishi T, Takatsu K, et al (2002). Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol, 17, 772-8.
8. Saelee P, Chuensumran U, Wongkham S, et al (2012). Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 13, 3489-93.
9. Sell LS (1990). Cancer markers of the 1990s. Clin Lab Med, 10, 1-37.
10. Suzuki M, Shiraha H, Fujikawa T, et al (???). Desgammacarboxyprothrombin is a potential autologous growth factorfor hepatocellular carcinoma. J Biol Chem, 280, 6409-15.
11. Weitz IC, Liebman HA (1993). Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology, 18, 990-7.
12. Xu J, Liu C, Zhou L, et al (2012). Distinctions between clinicopathological factors and prognosis of alphafetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62.
13. Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol , 45, 1272-82.
14. Ye JZ, Miao ZG, Wu FX, et al (2012). Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Asian Pac J Cancer Prev, 13, 1771-7.